The aim of this study was to investigate frequency and degree of ED in patients with severe sleep apnea and to evaluate the results of only continuous positive airway pressure (CPAP) therapy on ED in patients with severe obstructive sleep apnea syndrome (OSAS). This was a prospective clinical trial study. Patients with severe sleep apnea (40) were randomized into two groups. Multiple questionnaire investigation and laboratory evaluation were performed for ED, severity of OSAS and psychological status. Group 1 was treated with CPAP and group 2 was treated with only antidepressant medication for at least 1 month. Patients were evaluated after 1 month of therapy and compared with initial ones. Before CPAP, the International Index of Erectile Function (IIEF)-5 scores were significantly correlated only with body mass index (BMI; P ¼ 0.007) and not correlated significantly with Epworth Sleepiness Scale scores (P ¼ 0.286), lowest SaO 2 (P ¼ 0.182), Beck's Depression Inventory scores (P ¼ 0.302) and apnea/hypopnea index (P ¼ 0.279). After 1 month of regular CPAP usage, mean value of IIEF-5 score was 15.71 ± 5.12 before CPAP and were improved up to 19.06 ± 3.94, statistically significant. All subjects responded positively to the CPAP treatment and their erection status was improved positively. We have found a correlation between severe OSAS and ED. CPAP is effective in improvement of sexual performance of these patients.
Introduction
Obstructive sleep apnea syndrome (OSAS) is a recurrent upper airway occlusion characterized by cessation or reduction of breathing during sleep, with consequent blood oxygen desaturation and sleep fragmentation. In recent years, OSAS has become a common and serious problem, especially in overweight and older patients and is usually associated with a number of different systemic complications, such as hypertension, hyperlipidemia, hypercholesterolemia and cardiovascular heart disease. 1, 2 Although not yet certain, the mechanism underlying these complications is likely to be multifactorial, involving recurrent intermittent hypoxia and increased sympathetic activation. 3, 4 Erectile dysfunction as a symptom of OSAS was first described in 1977 and has been reported since then by others. 5 ED is characterized by the National Institutes of Health as the persistent or recurrent inability to achieve or maintain an erection sufficient for satisfactory sexual intercourse. 6 Erection is an event that involves the integration of psychological, neurological, endocrinological and vascular systems. Any reduction in this cooperation may cause ED.
OSAS is a multisystem disease but the causative mechanism of OSAS for ED is unclear. Many theories have been described, including impairment of sacral segment function in patients with OSAS, which was thought by Fanfulla et al. 1 to represent an early sign of nerve involvement causing ED. Otherwise, Margel et al. 7 suggested that morning tiredness and the respiratory disturbance index were predictive factors for ED, but only in patients with severe OSAS. Feldman et al. 8 reported the presence of ED in 79% of the overweight or obese patients with OSAS. ED may also appear as a psychological factor, especially with major depressive disorders, which is one of the most important problems in patients with OSAS. 9 Rapid eye movement sleep, or REM sleep, is often fragmented in patients with depression and OSAS, which leads to ED. 10 Essentially, any disorder that alters the basic sleep pattern, particularly REM sleep, may also alter the erection pattern. There are also many physiological challenges associated with OSAS that can define a relationship between OSAS and ED, such as increased sympathetic tone, endothelial dysfunction and intermittent hypoxia. However, the underlying mechanisms have not yet been well studied.
Nasal continuous positive airway pressure (CPAP) treatment is the gold standard treatment for patients with OSAS. The effect of CPAP on ED has also been studied, with limited efficiency. 11 Perimenis et al.
6
studied CPAP alone and CPAP with sildenafil in patients with OSAS with ED and found that sildenafil in combination with CPAP appears clearly superior to CPAP alone. In this study, we have evaluated patients with severe OSAS who had been advised to undergo CPAP treatment. Because of the association of many systemic problems including ED, the frequency and severity of ED was evaluated in these patients with severe OSAS before and after at least 1 month of nasal CPAP treatment. It is well known that CPAP is the best treatment for OSAS, but its effectiveness as a sole treatment for ED is unclear. The aim of our study was to evaluate ED in only patients with severe OSAS who needed nasal CPAP treatment and to determine the effects of only CPAP therapy on ED in these cases.
Patients and methods
The study included 40 consecutive men diagnosed with severe OSAS with polysomnographic examination in our sleep laboratory at the Istanbul Education and Research Hospital. Patients were considered to have severe OSAS when their apnea/hypopnea index (AHI) was more than 30 events per hour. Exclusion criteria from the study were use of nitrates, abnormal hormonal status, previous ED treatment, hypertension, diabetes mellitus, peripheral neuropathic disease, prostate cancer, pelvic trauma history, renal transplantation, aortic aneurysm, spinal cord injury, endocrine disturbances, penile deformity, alcohol abuse, psychotropic drug intake, presence of chronic and severe acute psychiatric disorders, chronic medical illness, cardiovascular diseases, and metabolic and neurological disorders. All subjects with mild and moderate OSAS (AHIo30 events per hour) were also excluded from the study.
The five questions of the International Index of Erectile Function-5 (IIEF-5) were performed to determine the frequency and severity of ED by a sexologist. All patients underwent biochemical and hormonal testing, including testosterone, prolactin, thyroid function, follicle stimulating hormone, luteinizing hormone and dehydroepiandrosterone. Patients with any presence of predisposing factors for ED were excluded from the study. The psychological status of patients was evaluated with Beck's Depression Inventory (BDI) score by a psychiatrist. Patients taking psychotropic drugs or presenting with chronic and severe acute psychiatric disorder (psychosis), metabolic or neurological disorders known to induce peripheral neuropathy or ED, abnormal hormonal status, previous ED treatment, unregulated hypertension, diabetes mellitus, peripheral neuropathic disease, pelvic trauma history, spinal cord injury and penile deformity were excluded from the study. The technologist who performed the polysomnography and the physicians who performed the evaluation for ED and psychological status were blind to the each other's results and to the patients.
All patients were randomized into two main groups. Randomization was made by a table of random numbers. Group 1 was treated with CPAP for 1 month and group 2 was treated with an antidepressant drug (selective serotonin reuptake inhibitor, 25 mg per day) orally for 1 month without CPAP. Selective serotonin reuptake inhibitor drugs are a new-generation antidepressant drugs used in treatment of patients with depression and that may cause ejaculation problems, without ED. Both groups were reevaluated with the same questionnaires and laboratory investigations after 1-month treatment.
The study was performed according to the Ethical Principles for Medical Research Involving Human Subjects (World Medical Association, The Declaration of Helsinki Principles, 2000). Written informed consent was obtained from all patients.
Polysomnography
All volunteers were evaluated for full-night polysomnography (Embla S7000; Embla Co., Broomfield, CO, USA) for two consecutive nights for diagnosis and one additional night for the therapeutic titration. A minimum of 7 h of recording time was obtained. During recording, surface electrodes were placed to obtain an electroencephalogram (at positions C3/A2, C4/A1, O1/A2 and O2/A1), a bilateral electrooculogram, chin, intercostal and bilateral anterior tibialis electromyogram and electrocardiogram. Respiration was monitored as follows: airflow was measured with a nasal cannula/pressure transducer system and a mouth thermocouple; chest and abdominal efforts were measured with uncalibrated respiratory plethysmographic belts, arterial oxygen saturation (SaO 2 ) was measured with pulse oximetry, snoring sounds were measured with a neck ED in severe sleep apnea patients U Taskin et al microphone and body position movements were measured with a mercury gauge.
Sleep recordings were scored using the international criteria. 12 According to the American Academy of Sleep Medicine, 12 apnea was defined as complete cessation of airflow for at least 10 s, hypopnea was defined as the reduction in airflow of at least 50% for 10 s or more or of reduction in breathing of less than 50% associated with 3% desaturation of oxyhemoglobin. The number of apnea and hypopnea episodes per hour of sleep is termed the AHI. Patients with an AHI of more than 30 were designated as patients with severe OSAS. 13 Questionnaires Scores from the following scales and questionnaires were documented before and after at least 1 month of CPAP therapy: the five questions of IIEF-5, 14 
BDI
15 and the Epworth Sleepiness Scale (ESS). 16 The ESS is a simple eight-item scale that evaluates the change in falling asleep in daily situations. The ESS consists of a possible total score ranging from 0 to 24; a normal score is less than 10. IIEF-5 includes five items that focus on erectile function and intercourse satisfaction. This test was shown to be an excellent diagnostic test for ED. 14 These questions correspond to questions 15, 2, 4, 5 and 7 of the original international index. For each question, scores ranged from 1 to 5, with a minimum score of 5 and maximum score of 25 for the five questions. A higher score means better erectile function. Scores between 5 and 7 were classified as severe ED. Patients also answered the 21 questions of BDI for analysis of psychological condition. 15 Scores ranged from 0 to 63 (0-13 normal; 14-19 mild; 20-28 moderate and 29-63 severe). Higher scores define a depth of psychological problems. 
Statistical analysis

Results
A total of 40 men with severe OSAS were included in the study and randomized into two groups. Patients ranged in age from 29 to 62 years (mean age 52.06 ± 8.02 years). All subjects were evaluated according to age, body mass index (BMI), hormonal status, AHI, lowest SaO 2 , IIEF-5, BDI and ESS scores. There were no significant differences between two groups with respect to age, BMI and AHI. Group 1 consisted of 20 patients with severe OSAS (mean age 51.05 ± 7.28 years). CPAP treatment was performed on all patients for 1 month. Two patients could not tolerate the treatment and one other patient left the follow-up. The remaining 17 patients completed the study in group 1. Twenty patients (mean age 53.05±6.65 years) were included in group 2. Antidepressant medication was given to all patients for 1 month. Three patients left the follow-up and two patients could not take the medication regularly. Fifteen patients completed study in group 2.
In group 1 subjects, before CPAP treatment, the mean AHI score was 35±19.3, ranging from 32 to 85. The lowest SaO 2 ranged from 64 to 94, mean score was 83.1 ± 15. AHI was not significantly correlated with BMI (P ¼ 0.282), IIEF-5 (P ¼ 0.279), ESS (P ¼ 0.351) or lowest SaO 2 values (P ¼ 0.183), but significant correlation was obtained with BDI (P ¼ 0.016). BMI was significantly correlated with IIEF-5 (P ¼ 0.007), ESS (P ¼ 0.006) and lowest SaO 2 values (P ¼ 0.053), but not significantly correlated with BDI (P ¼ 0.409) and AHI (P ¼ 0.282). IIEF-5 scores were significantly correlated only with BMI (P ¼ 0.007) and not correlated significantly with ESS (P ¼ 0.286), lowest SaO 2 (P ¼ 0.182), BDI (P ¼ 0.302) and AHI (P ¼ 0.279).
After 1 month of regular CPAP usage (compliance: mean daily 7 h per 7 days), group 1 subjects had no significant change in BMI and hormonal status (P40.05); however, the mean value of the IIEF-5 was improved up to 19.06 ± 3.94, which was statistically significant (Pp0.001). In addition, the mean values of BDI and ESS were significantly improved from 14.06 ± 6.58 to 5.12 ± 12 (Pp0.001) and from 10.06±1.95 to 2.00±1.06, respectively (Pp0.001) ( Table 1) .
After considering the potentially negative function of the lowest SaO 2 on erection, we considered two subgroups of subjects based on the lowest SaO 2 . Group 1 (with lowest SaO 2 p80%) consisted of nine men; in group 2 (with lowest SaO 2 480%) eight men were included. The results of IIEF-5, BDI and ESS Tables 2 and 3 . There were no statistically significant differences in these scores between group 1 and group 2 (PX0.05). There were statistically significant positive changes in IIEF-5, BDI and ESS scores after CPAP therapy in group 1 (P ¼ 0.011, P ¼ 0.08 and P ¼ 0.07, respectively). In group 2 subjects, IIEF-5, BDI and ESS scores were also improved and the differences were statistically significant after CPAP therapy (P ¼ 0.011, P ¼ 0.012 and P ¼ 0.012, respectively). In group 2 subjects, before antidepressant therapy, the mean AHI score was 33±21.7, ranging from 30 to 78. The lowest SaO 2 ranged from 66 to 92, mean score was 82.1 ± 21. The mean BDI, IIEF-5 and ESS scores were 12.06±8.7, 22±9.7 and 10.0±3.4 respectively. BDI were not correlated with AHI (P ¼ 0.412), BMI (P ¼ 0.075), lowest SaO 2 (P ¼ 0.056) or IIEF-5 (P ¼ 0.223). IIEF-5 was slightly correlated with lowest SaO 2 (P ¼ 0.039) and not correlated with AHI (P ¼ 0.401), BMI (P ¼ 0.092) and BDI (P ¼ 0.223).
After 1 month of regular medication, group 2 subjects had no significant change in BMI and hormonal status (P40.05). There was also no significant difference found between initial and control mean values of IIEF-5 and ESS. The mean IIEF-5 score was changed from 13.13 ± 3.02 to 14.13±3.99 after medical therapy; however, this was not statistically significant (P ¼ 0.19). The mean BDI score was improved from 18.53 ± 3.02 to 5.00 ± 3.04 and was statistically significant (P ¼ 0.001). The lowest SaO 2 was also not changed after medical therapy.
Discussion
ED, the inability to achieve or maintain an erection sufficient for sexual intercourse, 17 can arise due to hormonal, 18 vascular, 19 neurological, psychological and endocrinological disorders. 13 It is evident that obese men have a higher incidence of ED affecting their sexual life. 20 Esposito et al. 21 found that loss of 10% or more total body weight by reducing calorie intake and increasing levels of physical activity had a higher rate of weight loss and improvement in ED than in controls. Because OSAS is often seen in obese patients, the risk of ED is frequent in these cases. In our subjects, BMI predictive for obesity was higher than baseline in all severe cases of OSAS, but there was no positive correlation between IIEF-5 scores and BMI scores before and after CPAP therapy. Hypoxia is also a predictive factor for ED. Gonçalves et al. 22 reported a high percentage of low SaO 2 (o80%) in OSAS with ED. In their study, severe ED was seen as SaO 2 percentage decreased. Fanfulla et al.
1 also presented similar results. However, in this study, although SaO 2 declined in all severe OSAS subjects, there was no correlation between severity of hypoxia and IIEF-5 or AHI scores. Hypoxia was positively and significantly changed after CPAP therapy, as were IIEF-5, ESS and AHI scores.
The hormonal profile may also affect ED, especially in patients with OSAS. In one study, both total and free testosterone levels were found to be lower in patients with OSAS. A negative correlation between polysomnographic parameters (AHI, min SaO 2 ) and testosterone levels were found. The severity of hypoxia during sleeping hours was thought to be an additional factor in reducing testosterone levels, regardless of BMI and abdominal fatness. 23 However, in one study, use of CPAP did not change hormonal activity, 24 as in our cases where hormonal profiles were normal before and after CPAP therapy. In this previous study, the investigators indicated that the improvement of symptoms without change in hormonal profile was related directly to CPAP. In terms of psychological problems, apnea-induced daytime somnolence or the depressed mood commonly seen in OSAS cases may cause ED. 25 Although sexual dysfunction, including ED in men, is a common symptom of depression, sexual dysfunction is also a frequent adverse effect of treatment with most antidepressants. 26 Among them, selective serotonin reuptake inhibitors have less adverse effect on erection. 27 Therefore, treatment for depression with these drugs ED in severe sleep apnea patients U Taskin et al decreases the side effects on erection. As in our study, depression is commonly seen in patients with severe OSAS; ED might be due to depression apart from the metabolic disturbances of OSAS. Therefore, antidepressant drugs were given to only one group to improve the psychological condition of patients. However, the use of antidepressant therapy without CPAP for ED problems for 1 month resulted in no improvement their IIEF-5 scores, although BDI scores were restored to normal ranges. This indicates that psychological problems are not the main predisposing factors in OSAS cases with ED; metabolic disturbances are more effective on ED in these patients. Improvement of ED after only CPAP therapy supports this conclusion in our study. It has been reported that CPAP treatment significantly improves problems of OSAS and that subjects with more severe apnea may benefit more. 19 Treatment of ED in OSAS is still controversial and varies according to cause, but the cause of ED remains unclear. Consequently, without defining the cause of ED, many drugs such as sildenafil are used for treatment. 13 The use of sildenafil with CPAP was reported by Perimenis et al., 6 whereas Margel et al.
28
reported the long-term effects of CPAP treatment on ED in patients with OSAS. The latter study showed that only 20% of patients with OSAS might show improved erectile function solely with CPAP treatment. 28 This lower success rate might be due to inclusion of all patients with OSAS from mild to severe ones. In our study, we investigated only patients with severe OSAS who were more prone to ED and CPAP was advised routinely in all these cases. Patel et al. 19 showed a significant improvement in objective and subjective measures of sleepiness in patients with OSAS with ED. It was unclear that improvement was due to the effectiveness of CPAP or whether it was because all patients had severe OSAS. In another study, sildenafil increased CPAP effectiveness in patients with mild OSAS when compared with CPAP alone. 6 In contrast, in study by Margel et al., 28 CPAP treatment deteriorated erectile function. This may be due to the improper use of CPAP.
This study shows that severe OSAS is strongly related to ED in all of the dimensions we assessed. ED scores become worse as AHI improved. Another important finding was the worsening of patient psychology as AHI increased. Thus, patients became depressive, which resulted in ED. However, it was not clear whether ED was only due to psychological problems in the OSAS cases. CPAP treatment in patients with OSAS with ED resulted in a gradual improvement in IIEF-5, ESS and BDI scores. Symptoms of ED were diminished after CPAP treatment. In addition, as the BDI scores improved, the ED symptoms also improved. Improved alertness and decreases in underlying reactive depression may have contributed to the observed improvement in ED. In summary, ED was seen as a common complication in patients with severe OSAS and their ED symptoms were improved after CPAP treatment.
Conclusion
We have confirmed a correlation between severe OSAS and ED. CPAP treatment is effective for improvement of sexual performance. In addition, the AHI is also a predictive factor for OSAS. There were no changes in hormonal profiles in patients with OSAS, but hypoxia was the most important measurement in evaluating in OSAS with ED, besides psychological condition. Therefore, in case of treatment of patients with ED, OSAS should be kept in mind. Future studies about the relationship of OSAS and ED should now focus on the mechanism of ED in these patients and evaluate the effectiveness of CPAP and antidepressant medical therapy in conjunction as a treatment for ED.
